Want to see CH:MEDX full AI Analyst Report?
MEDX Stock Chart & Stats
CHF8.91
-CHF0.06(-0.73%)
At close: 4:00 PM EDT
CHF8.91
-CHF0.06(-0.73%)
Day’s Range― - ―
52-Week RangeCHF7.61 - CHF12.36
Previous CloseN/A
Volume153.47K
Average Volume (3M)51.97K
Market Cap
CHF357.74M
Enterprise ValueCHF610.90
Total Cash (Recent Filing)CHF111.30M
Total Debt (Recent Filing)CHF319.40M
Price to Earnings (P/E)3596.0
Beta0.96
Next Earnings
Feb 23, 2027EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend Yield1.11%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding41,262,370
10 Day Avg. Volume49,229
30 Day Avg. Volume51,967
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.08
Price to Sales (P/S)1.02
P/FCF Ratio13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.52
Revenue Forecast (FY)CHF443.29M
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive operating and free cash flow provide internal funding for investment, debt service, and product development. This supports financial resilience even though recent cash conversion has been uneven.
Profitability RecoveryThe return to positive net income indicates operational improvement after the prior weakness. If sustained, it can strengthen reinvestment capacity and improve the economics of medmix’s engineered product portfolio.
Recurring Engineered Product DemandConsumables and customer-specific components can generate repeat demand as customers continue production or clinical activity. Application expertise and design support may also reinforce customer integration and product pull-through.
Bears Say
Declining RevenueRecent revenue contraction signals softer demand and limits operating leverage. Continued weakness could constrain investment, reduce manufacturing efficiency, and make the profitability recovery more difficult to sustain.
Thin Profit MarginsVery limited margins and low returns on equity leave little buffer against input costs, pricing pressure, or demand volatility. The business therefore remains vulnerable to small operating setbacks despite improved profitability.
Higher Leverage And Volatile FCFHigher leverage reduces financial flexibility, while the sharp FCF decline suggests cash outcomes can vary with working capital or investment needs. Together, these factors may limit resilience during prolonged demand weakness.
medmix AG News
MEDX FAQ
What was medmix AG’s price range in the past 12 months?
medmix AG lowest stock price was CHF7.61 and its highest was CHF12.36 in the past 12 months.
What is medmix AG’s market cap?
medmix AG’s market cap is CHF357.74M.
When is medmix AG’s upcoming earnings report date?
medmix AG’s upcoming earnings report date is Feb 23, 2027 which is in 157 days.
How were medmix AG’s earnings last quarter?
medmix AG released its earnings results on Jul 23, 2026. The company reported CHF0.32 earnings per share for the quarter, missing the consensus estimate of CHF0.35 by -CHF0.03.
Is medmix AG overvalued?
According to Wall Street analysts medmix AG’s price is currently Overvalued.
Does medmix AG pay dividends?
medmix AG pays a Annually dividend of CHF0.1 which represents an annual dividend yield of 1.11%. See more information on medmix AG dividends here
What is medmix AG’s EPS estimate?
medmix AG’s EPS estimate is 0.42.
How many shares outstanding does medmix AG have?
medmix AG has 41,262,370 shares outstanding.
What happened to medmix AG’s price movement after its last earnings report?
medmix AG reported an EPS of CHF0.32 in its last earnings report, missing expectations of CHF0.35. Following the earnings report the stock price went down -4.01%.
Which hedge fund is a major shareholder of medmix AG?
Currently, no hedge funds are holding shares in CH:MEDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
medmix AG
Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixing, application, and injection of liquids across various viscosities, serving diverse healthcare, consumer, and industrial markets worldwide. The company operates through five key divisions: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers essential tools such as mixing tips, dispensers, needles, and accessories, alongside support services for applications including prosthetics, restorative procedures, anesthesiology, and cosmetic dentistry. In its Drug Delivery segment, Medmix develops critical devices for administering medications like fertility drugs, growth hormones, and treatments for specific diabetes conditions, osteoporosis, and rare diseases. The Surgery segment provides specialized mixing and delivery systems utilized for injecting bone cement and applying hemostatic sealants to manage both internal and external wounds during surgical interventions. For industrial clients, the Industry division produces robust dispensers, cartridges, and mixers for two-component adhesives and sealants, indispensable in sectors such as construction, transportation, electronics, infrastructure, and broader manufacturing. Lastly, the Beauty segment supplies micro brushes, mascara applicators, lip gloss, and concealers. Medmix AG markets its comprehensive product range under well-recognized brands, including Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka.
Technical Analysis
Georg Fischer AG
―
Komax Holding AG
―
Mikron Holding AG
―
Sulzer AG
―
StarragTornos Group AG
―








